CJC-1295 (No DAC) vs Epithalon: Mechanism, Half-Life & Research Use

Core Structural and Functional Differences

CJC-1295 (No DAC) is a modified 29-amino acid synthetic peptide derived from the naturally occurring growth-hormone-releasing hormone (GHRH 1-29). It acts as a GHRH analog and is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. In contrast, Epithalon (also known as Epitalon) is a short synthetic tetrapeptide consisting of four amino acids (Ala-Glu-Asp-Gly) designed to mimic the biological activity of pineal-derived epithalamin, primarily investigated for its interactions with nuclear chromatin and telomerase expression.

The primary distinction between these two research compounds lies in their cellular target sites and downstream effector cascades. CJC-1295 (No DAC) binds directly to membrane-bound GHRH receptors on pituitary somatotropes, initiating a cyclic adenosine monophosphate (cAMP)-dependent intracellular signaling stream that induces growth hormone exocytosis. Epithalon exerts its effects predominantly within the nuclear envelope, where preclinical models demonstrate its ability to induce chromatin decondensation, activate promoter regions of the telomerase reverse transcriptase (TERT) gene, and influence circadian peptide secretion via pineal interaction.

For laboratory researchers assembling study designs, these compounds cannot be used interchangeably. Investigators seeking to study metabolic flux, somatotropic axis modulation, or localized tissue repair pathways typically utilize CJC-1295 (No DAC). Conversely, laboratories focused on cellular senescence, telomere attrition rates, gene expression alteration, or epithalamic signaling pathways select Epithalon as their baseline research candidate.

Preclinical Criteria and Specifications

To evaluate how CJC-1295 (No DAC) and Epithalon align with specific laboratory requirements, the following table details their biochemical, structural, and pharmacokinetic parameters observed in preclinical literature:

| Criteria | CJC-1295 (No DAC) | Epithalon | | :--- | :--- | :--- | | **Mechanistic Class** | GHRH Analog / GH Secretagogue | Telomerase Activator / Epithalamic Mimetic | | **Primary Receptor Target** | Pituitary GHRH Receptor (GHRHR) | Nuclear Chromatin / TERT Promoter Region | | **Reported In Vivo Half-Life** | ~30 minutes (Rodent models) | ~30–60 minutes (Plasma rapid clearance) | | **Molecular Formula / Weight** | C152H252N44O42 / 3367.9 g/mol | C14H22N4O9 / 390.35 g/mol | | **Solubility Profile** | Water, Bacteriostatic Water, PBS | Water, Bacteriostatic Water, Saline | | **Typical Preclinical Model** | Rodent tissue repair & GH pulsatility | Cell senescence & non-human primate aging | | **Vial Sizes Available** | 2mg, 5mg, 10mg lyophilized powder | 10mg, 20mg, 50mg lyophilized powder | Researchers cross-referencing these specifications within our all peptides catalog should account for the differing molar masses when preparing equimolar concentrations for in vitro assays.

Mechanism of Action: CJC-1295 (No DAC) and the GHRH Pathway

CJC-1295 (No DAC), also designated as Modified GRF 1-29, incorporates four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) compared to native GHRH 1-29. These chemical modifications increase enzymatic resistance to dipeptidyl peptidase-IV (DPP-IV), which rapidly cleaves native GHRH at the second amino acid position (Ala2). By conferring stability against immediate cleavage, CJC-1295 (No DAC) maintains a prolonged binding affinity for the growth-hormone-releasing hormone receptor (GHRHR).

Upon receptor engagement on anterior pituitary somatotropes, CJC-1295 (No DAC) triggers the activation of adenylate cyclase via G-protein-coupled signaling. This activation elevates intracellular cAMP, subsequently stimulating protein kinase A (PKA) and calcium influx. In vitro and animal studies demonstrate that this cascade leads to transcript activation of the GH gene and exocytosis of GH granules. Because it lacks the Drug Affinity Complex (DAC) maleimidopropionic acid moiety, it does not permanently bind to circulating serum albumin, permitting a physiological, pulsatile pattern of GH release rather than a constant, continuous baseline elevation.

The sustained elevation of GH drives hepatic and peripheral synthesis of insulin-like growth factor 1 (IGF-1). In tissue repair research, this elevated IGF-1 axis promotes protein translation, amino acid uptake, collagen deposition, and cellular proliferation in musculoskeletal and epithelial cell lines. Preclinical evidence suggests that this localized cascade accelerates matrix remodeling without inducing long-term pituitary receptor desensitization when administered in physiological pulses.

Mechanism of Action: Epithalon and Telomerase Activation

Epithalon operates through a non-receptor-mediated mechanism involving direct interaction with nuclear structures and genomic regulation. Developed as a synthetic analogue of the pineal peptide epithalamin, Epithalon consists of the sequence L-alanyl-L-glutamyl-L-aspartyl-glycine. Preclinical assays demonstrate that this small tetrapeptide can cross nuclear membranes and bind directly to specific histone motifs and promoter regions on DNA strands.

The primary mechanism attributed to Epithalon in cellular senescence models is the reactivation or upregulation of telomerase, the ribonucleoprotein enzyme complex responsible for elongating terminal chromosomal DNA repeats (TTAGGG). In human somatic cell cultures and aging rodent assays, Epithalon administration has been associated with the induction of the catalytic subunit of telomerase (TERT). By promoting telomerase expression, the compound reduces the rate of critical telomere shortening during successive mitotic cycles, thereby delaying the onset of the Hayflick limit in senescent fibroblasts.

Additionally, research models indicate Epithalon modulates epigenetic stability through chromatin remodeling. In vitro data demonstrate its capacity to alter DNA methylation patterns and reactivate silenced genes in aged tissues. Furthermore, pineal culture experiments show that Epithalon stimulates melatonin synthesis via upregulation of arylalkylamine N-acetyltransferase (AANAT), establishing its secondary role as a regulator of neuroendocrine circadian rhythms in animal research.

Pharmacokinetics and Degradation Profiles

The pharmacokinetic profiles of CJC-1295 (No DAC) and Epithalon present unique handling requirements for quantitative research protocols. Native GHRH exhibits a terminal half-life of fewer than 10 minutes in rodent models due to rapid cleavage by DPP-IV and neutral endopeptidases. Modified GRF 1-29 (CJC-1295 No DAC) extends this half-life to approximately 30 minutes in vivo, providing a sufficiently broad experimental window to measure total GH peak amplitude while retaining natural pulsatile decay curves.

Epithalon features a similarly short systemic half-life, clearing rapidly from vascular circulation within 30 to 60 minutes following administration in animal models. However, its downstream biological activity—specifically telomerase upregulation, enzymatic expression changes, and chromatic structural alterations—persists well beyond its physical elimination from blood plasma. Preclinical assays suggest that transient exposure to Epithalon initiates epigenetic transcription cascades that remain active in cell cultures over extended periods.

When evaluating analytical batch reports, researchers must verify peptide purity and structural integrity using a lot-specific certificate of analysis (COA). Both compounds are prone to enzymatic degradation if exposed to room temperature liquids or repeated freeze-thaw cycles, making precise reconstitution and immediate cold-chain storage critical for consistent pharmacokinetic outcomes.

Experimental Applications: Tissue Repair vs. Cellular Senescence

The selection between CJC-1295 (No DAC) and Epithalon depends heavily on the primary biological endpoints under investigation in the research protocol. CJC-1295 (No DAC) is predominantly deployed in studies evaluating endocrine axis dynamics, muscle protein synthesis, tendon and ligament repair, cartilage regeneration, and systemic metabolic rate adjustments.

For instance, rodent injury models utilizing CJC-1295 (No DAC) examine the rate of collagen deposition, fibroblast migration, and satellite cell activation following localized mechanical stress. Because the peptide induces elevated serum IGF-1, it serves as an effective positive control for investigating post-injury tissue regeneration and osteoblast activity.

Epithalon, conversely, is utilized in protocols focused on bio-gerontology, genomic stability, carcinogenesis inhibition, and endocrine rejuvenation. Typical research designs incorporate Epithalon to study telomere attrition in culture plates, lifespan extension parameters in Drosophila or rodent cohorts, tumor incidence rates in aging populations, and restore pineal responsiveness to light-dark cycles.

Researchers investigating systemic biological preservation may occasionally study these pathways in parallel, but their assays measure distinct variables: CJC-1295 (No DAC) measures somatotropic hormone amplitudes and cellular hypertrophy, while Epithalon quantifies telomere base-pair lengths, TERT gene expression, and oxidative stress biomarkers.

Comparative Analysis within Peptide Classes

To contextualize CJC-1295 (No DAC) within the broader GH secretagogue landscape, it is helpful to compare it against related GHRH analogs and ghrelin receptor agonists. For example, CJC-1295 with DAC includes a maleimidopropionic acid reactive group that covalently binds to circulating albumin, extending its biological half-life to over 6 to 8 days in animal models and creating a non-pulsatile, continuous baseline elevation of GH and IGF-1.

When designing synergistic secretagogue models, researchers frequently combine GHRH analogs like CJC-1295 (No DAC) with growth hormone secretagogue receptor (GHSR) agonists such as Ipamorelin or GHRP-2. In vitro assays demonstrate that co-activation of GHRH and GHSR receptors yields a synergistic release of GH far greater than the additive sums of either peptide administered in isolation.

Epithalon occupies a distinct biochemical niche alongside short pineal peptides such as Epithalamin and synthetic bioregulators like Thymalin. While ghrelin agonists and GHRH analogs promote tissue hypertrophy via receptor-mediated intracellular signaling cascades, Epithalon directly targets nuclear architecture and genetic regulation, representing a fundamental shift from hormone receptor agonism to gene transcription modulation.

Laboratory Protocols: Reconstitution and Storage Parameters

Proper handling and solution preparation are mandatory to preserve the primary peptide structures of both CJC-1295 (No DAC) and Epithalon. Both research compounds are supplied by PX1 Research as highly purified, sterile lyophilized powders sealed under inert gas to prevent oxidation.

Reconstitution should be performed using laboratory-grade Bacteriostatic Water or Sterile Normal Saline, depending on the requirements of the downstream in vitro assay or animal model. When reconstituting, the solvent should be gently dripped down the inner glass wall of the vial rather than sprayed directly onto the lyophilized cake to prevent shear stress and peptide denaturation. Researchers can calculate exact solvent-to-peptide ratios using our online reconstitution calculator.

Lyophilized vials should be stored at -20°C prior to reconstitution for long-term stability. Once reconstituted in liquid solution, aliquots of CJC-1295 (No DAC) and Epithalon are stable at 2°C to 8°C for short experimental windows (typically up to 14–28 days when preserved with benzyl alcohol). For extended usage, aliquots should be flash-frozen at -80°C to prevent repeated freeze-thaw degradation cycles.

PX1 Research Quality Assurance and Analytical Verification

Reliable preclinical research requires compounds of precise mass, verified sequence identity, and total freedom from cytotoxic contaminants. PX1 Research manufactures all research peptides in USA-based, GMP-compliant facilities utilizing advanced solid-phase peptide synthesis (SPPS) platforms.

Every production lot undergoes rigorous analytical testing at an independent, ISO 17025 accredited laboratory. Quality control procedures incorporate High-Performance Liquid Chromatography (HPLC) to verify chemical purity above 99% and Mass Spectrometry (MS) to confirm exact molecular mass against theoretical frameworks. Furthermore, all lots undergo chromogenic LAL assays to ensure endotoxin levels remain strictly below safe thresholds for sensitive cell culture and animal research.

Principal investigators and laboratory procurement officers can view comprehensive test results in our publicly available research library or submit inquiries for bulk facility sourcing via our wholesale portal.

Protocol Mapping: Selecting the Right Compound for Your Model

Determining whether CJC-1295 (No DAC) or Epithalon is appropriate for a specific research framework depends on the biological pathways under interrogation. Below is a structured protocol selection guide based on primary experimental targets:

**Select CJC-1295 (No DAC) for protocols investigating:** - Pituitary somatotrope receptor kinetics and cAMP-dependent signaling cascades. - Pulsatile growth hormone release dynamics and acute serum IGF-1 elevation. - Acceleration rates of musculoskeletal, tendon, or dermal tissue repair in rodent injury models. - Synergistic receptor crosstalk between GHRH analogs and ghrelin mimetics.

**Select Epithalon for protocols investigating:** - Upregulation of enzymatic TERT transcription and telomere length preservation in senescent cell lines. - Epigenetic modification, histone binding, and chromatic decondensation. - Pineal gland reactivity, melatonin synthesis regulation, and circadian rhythm maintenance in aging models. - Suppression of spontaneous carcinogenesis and free radical scavenging mechanisms in long-term rodent lifespan studies.